Eb-Pt-Car-Nk-S
Advanced or Metastatic Solid Tumors
Beijing BiotechCell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
61 Active assets in the Advanced or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Hanmi Pharmaceutical Company Limited | Phase 1/2 | B |
Cyclophosphamide Beijing Biotech | Phase 1/2 | B |
Pembrolizumab Hanmi Pharmaceutical Company Limited | Phase 1/2 | B |
Eloxatin ASLAN Pharmaceuticals | Phase 1/2 | CCC |
Capecitabine ASLAN Pharmaceuticals | Phase 1/2 | CCC |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →